FNCH vs. CLYM, IZTC, SNTI, PYXS, GALT, CLLS, ELUT, TNYA, GNTA, and STRO
Should you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include Climb Bio (CLYM), Invizyne Technologies (IZTC), Senti Biosciences (SNTI), Pyxis Oncology (PYXS), Galectin Therapeutics (GALT), Cellectis (CLLS), Elutia (ELUT), Tenaya Therapeutics (TNYA), Genenta Science (GNTA), and Sutro Biopharma (STRO). These companies are all part of the "pharmaceutical products" industry.
Finch Therapeutics Group vs. Its Competitors
Climb Bio (NASDAQ:CLYM) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.
69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 0.8% of Climb Bio shares are owned by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Climb Bio has higher earnings, but lower revenue than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks.
Finch Therapeutics Group received 5 more outperform votes than Climb Bio when rated by MarketBeat users. However, 83.33% of users gave Climb Bio an outperform vote while only 52.63% of users gave Finch Therapeutics Group an outperform vote.
In the previous week, Climb Bio had 3 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 3 mentions for Climb Bio and 0 mentions for Finch Therapeutics Group. Climb Bio's average media sentiment score of 0.57 beat Finch Therapeutics Group's score of 0.00 indicating that Climb Bio is being referred to more favorably in the media.
Climb Bio's return on equity of -42.21% beat Finch Therapeutics Group's return on equity.
Climb Bio presently has a consensus price target of $9.00, indicating a potential upside of 608.66%. Given Climb Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Climb Bio is more favorable than Finch Therapeutics Group.
Climb Bio has a beta of -0.16, suggesting that its stock price is 116% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500.
Summary
Climb Bio beats Finch Therapeutics Group on 12 of the 17 factors compared between the two stocks.
Get Finch Therapeutics Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Finch Therapeutics Group Competitors List
Related Companies and Tools
This page (NASDAQ:FNCH) was last updated on 6/13/2025 by MarketBeat.com Staff
